Drugs with the potential to change the course of Alzheimer's disease are expected to be approved by mid-year in the UK. Healthcare services may need to change to ensure that all patients have equitable access to these new modifying anti-amyloid therapies, according to new research.
Drugs with the potential to change the course of Alzheimer's disease are expected to be approved by mid-year in the UK. Healthcare services may need to change to ensure that all patients have equitable access to these new modifying anti-amyloid therapies, according to new research.
In the UK, dementia care is mostly centred around psychiatry-led memory clinics in the community. In their current state, it is extremely unlikely that DMTs will be administered in these settings. Delivery of these new treatments will require a major restructure to existing dementia services -- from determining eligibility to delivery of the treatment itself, including follow-up. It will require additional staff and training across imaging, diagnostics and pathology, and other clinical services.
While a sizeable proportion of patients attending memory clinics may be referred for therapy for Alzheimer's disease, only a minority are likely to be suitable, once they have undergone biomarker testing. The researchers highlight an immediate need for biomarker testing to ensure that the right patients can be identified for these treatments.
Study co-lead, Professor Catherine Mummery, Consultant Neurologist at UCL and the National Hospital for Neurology and Neurosurgery, said:"We demonstrate that diagnostic resources affect the accuracy of diagnosis and referral habits, and that a collaborative networked approach is critical to developing a functioning treatment service in preparation for these new therapies."
This study was produced by researchers from a network of universities who form the Academic Health Science Centre for UCLPartners and in collaboration with a network of clinicians in memory clinics in London and the South East.
Healthy Aging Today's Healthcare Elder Care Alzheimer's Dementia Disorders And Syndromes Caregiving
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Here's an undervalued stock that can benefit from new Alzheimer's drugsThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »
Gov. Kay Ivey establishes Alabama School of Healthcare Sciences to combat healthcare worker shortageHelp is on the way for the nationwide healthcare shortage that is being felt in rural hospitals across Alabama.
Read more »
Exercising to beat Alzheimer's, plus a baby's renewed vision and new vaccine progressThe Fox News Health Newsletter brings you trending and important stories about health warnings, drug shortages, mental health issues and more in this weekly recap.
Read more »
AFA responds to approval of Alzheimer’s Drug by FDA Advisory CommitteeThis new drug works by slowing the progression of the disease when administered within the early stages of Alzheimer’s.
Read more »
Independent FDA Panel Endorses New Alzheimer’s Disease TreatmentAn FDA advisory panel unanimously gave a green light on Monday to the Alzheimer’s disease treatment donanemab for use during early stages of the disease.
Read more »
Eli Lilly's Alzheimer's drug donanemab advances as America's population agesAn advisory committee endorsing the drug says it's safe and effective. If approved by the FDA, donanemab would be the second drug on the market to slow the progression of the disease.
Read more »